IRIS UniCatt

Criscuolo, Marianna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.990
EU - Europa 3.512
AS - Asia 3.146
SA - Sud America 595
Continente sconosciuto - Info sul continente non disponibili 134
AF - Africa 95
OC - Oceania 14
Totale 12.486
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.845
SG - Singapore 1.393
DE - Germania 1.107
CN - Cina 804
SE - Svezia 513
BR - Brasile 473
IT - Italia 382
NL - Olanda 378
VN - Vietnam 269
FR - Francia 256
UA - Ucraina 200
IN - India 149
PL - Polonia 143
IE - Irlanda 129
GB - Regno Unito 114
ID - Indonesia 91
RU - Federazione Russa 73
FI - Finlandia 71
CA - Canada 61
BD - Bangladesh 59
JP - Giappone 59
HK - Hong Kong 58
TR - Turchia 48
MX - Messico 43
AR - Argentina 38
IQ - Iraq 35
ES - Italia 30
ZA - Sudafrica 30
PK - Pakistan 26
SA - Arabia Saudita 23
KR - Corea 20
NO - Norvegia 19
BE - Belgio 18
CO - Colombia 17
EC - Ecuador 17
AT - Austria 16
CL - Cile 14
AU - Australia 13
CI - Costa d'Avorio 12
JO - Giordania 12
UZ - Uzbekistan 11
VE - Venezuela 11
MA - Marocco 10
PH - Filippine 10
AE - Emirati Arabi Uniti 9
JM - Giamaica 9
LT - Lituania 9
CZ - Repubblica Ceca 8
EG - Egitto 8
IR - Iran 8
PY - Paraguay 8
BO - Bolivia 7
GR - Grecia 7
KE - Kenya 7
MY - Malesia 7
NP - Nepal 7
PE - Perù 7
PS - Palestinian Territory 7
RO - Romania 7
TH - Thailandia 7
DZ - Algeria 6
HN - Honduras 6
IL - Israele 6
AZ - Azerbaigian 5
CH - Svizzera 5
KZ - Kazakistan 5
CR - Costa Rica 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
HU - Ungheria 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BG - Bulgaria 3
GE - Georgia 3
HR - Croazia 3
KG - Kirghizistan 3
LV - Lettonia 3
MD - Moldavia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AM - Armenia 2
AO - Angola 2
BW - Botswana 2
BZ - Belize 2
EU - Europa 2
GH - Ghana 2
GT - Guatemala 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
PR - Porto Rico 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AI - Anguilla 1
AW - Aruba 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
Totale 12.337
Salva come PNG Salva come JPEG
Città #
Singapore 801
Chandler 550
San Jose 484
Ashburn 429
Amsterdam 350
Los Angeles 190
Frankfurt am Main 157
Chicago 139
Jacksonville 139
Beijing 138
Warsaw 127
Dublin 123
New York 122
San Mateo 111
Ann Arbor 109
Houston 98
Ho Chi Minh City 94
Woodbridge 94
Dearborn 92
Nanjing 92
Munich 90
Jakarta 82
Lauterbourg 82
Wilmington 82
Milan 74
Hefei 68
Hanoi 66
St Louis 62
Buffalo 59
Fairfield 58
Boston 55
Hong Kong 55
São Paulo 52
Rome 51
Dallas 47
Moscow 47
Tokyo 47
Hyderabad 46
Bremen 44
The Dalles 44
Cattolica 41
Nürnberg 40
Seattle 39
Nanchang 37
Redwood City 37
Santa Clara 37
Lawrence 34
Princeton 34
Orem 27
Shanghai 27
Hangzhou 26
Marseille 26
Salt Lake City 26
London 25
Montreal 25
Council Bluffs 23
Leawood 20
Phoenix 20
Cambridge 19
Mountain View 19
Shenyang 19
Brussels 18
Guangzhou 18
Kunming 18
Brooklyn 17
Da Nang 17
Izmir 17
Redmond 17
Seoul 17
Tianjin 17
Boardman 16
Chatsworth 16
Denver 16
Mexico City 16
Paris 16
Pune 16
Atlanta 15
Augusta 15
Kent 15
Poplar 15
Auburn Hills 14
Johannesburg 14
Philadelphia 14
Baghdad 13
Dhaka 13
Elk Grove Village 13
Falls Church 13
Jiaxing 13
Nuremberg 13
Tampa 13
Zhengzhou 13
Abidjan 12
Amman 12
Belo Horizonte 12
Chennai 12
Lappeenranta 12
Changsha 11
Hebei 11
Norwalk 11
Rio de Janeiro 11
Totale 6.813
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 639
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 437
Fanconi anemia gene variants in therapy-related myeloid neoplasms 332
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 305
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 266
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 245
Why methylation is not a marker predictive of response to hypomethylating agents 204
in Higher-Risk Myelodysplastic Syndromes and Low Blast Count Acute Myeloid Leukemia: Results of the BMT-AZA Prospective Study 202
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 200
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 195
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 194
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 194
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 190
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 188
Epigenetic changes in therapy-related MDS/AML 187
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 187
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 178
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 178
Clonal evolution in therapy-related neoplasms 178
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 177
Similarities and differences between therapy-related and elderly acute myeloid leukemia 172
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 171
Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report 171
Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience 167
Primary plasma cell leukemia followed by testicular plasmacytoma 166
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 158
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency 157
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 156
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 154
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 150
Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT 150
In vitro Effect of Eltrombopag Alone and in Combination With Azacitidine on Megakaryopoiesis in Patients With Myelodysplastic Syndrome 149
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS 147
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 146
Outcome of therapy-related myeloid neoplasms treated with azacitidine 142
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 142
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 141
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 139
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 137
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 137
Bloodstream infections caused by Escherichia coli in onco-haematological patients: Risk factors and mortality in an Italian prospective survey 135
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 134
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 131
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 130
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 128
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 125
Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper 125
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry 125
Therapy-related myeloid neoplasms: Clinical perspectives 121
Disseminated geosmithia argillacea infection in a patient with ph-positive acute lymphoblastic leukemia. Case report and literature review 119
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022 118
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry 117
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 111
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. 110
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders 109
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 107
Systemic mastocytosis revisited with an emphasis on skeletal manifestations 107
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 106
Rapid response of nodular CD30-positive mycosis fungoides to brentuximab vedotin 104
Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEM-12B study) 103
Second Neoplasms in Italian Patients with Hairy Cell Leukemia after Treatment with Cladribine: A Multicenter Investigation and Literature Review 103
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 103
Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath? 101
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 100
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome 99
A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: A prospective multicenter study of the SEIFEM group 99
Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality? 98
The validity of the fifth and the 10th Body Mass Index percentile as weight cut-offs for anorexia nervosa in adolescence: No evidence from quantitative and network investigation of psychopathology 98
Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope 97
Risk of infectious complications in patients with chronic lymphocytic leukemia in the era of BCR inhibitors: a retrospective single institution experience 95
Fungaemia in haematological malignancies: SEIFEM-2015 survey 92
The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis 91
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report 90
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study 90
A review of prophylactic regimens to prevent invasive fungal infections in hematology patients undergoing chemotherapy or stem cell transplantation 89
Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata 85
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 83
Revision of antifungal strategies definitions for invasive fungal infections (proven/probable/possible) in 461 patients with haematological malignancies (REDEFI-SEIFEM) 83
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 83
In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome 81
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients 72
Mastocytosis: One Word for Different Diseases 69
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 68
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 62
Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review 13
Clinical and immunological biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms 9
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 9
Efficacy and tolerability of mogamulizumab in mycosis fungoides and Sézary Syndrome: a monocentric retrospective study 8
Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide 7
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report 7
Determinants of survival in patients treated with CPX-351 for acute myeloid leukemia 5
Managing Invasive Fungal Infections During Allogeneic Hematopoietic Transplantation: A 2025 Update 4
Totale 12.486
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.031
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022582 0 0 8 29 50 35 13 119 36 72 94 126
2022/20231.435 185 204 122 264 77 177 49 110 155 20 52 20
2023/2024730 36 186 27 27 29 128 60 15 11 26 89 96
2024/20251.840 48 57 128 53 154 23 89 73 228 170 561 256
2025/20264.578 597 92 223 408 675 776 735 195 338 335 125 79
2026/2027451 179 272 0 0 0 0 0 0 0 0 0 0
Totale 12.486